Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 23:117:e200501.
doi: 10.1590/0074-02760200501. eCollection 2022.

The translational challenge in Chagas disease drug development

Jadel M Kratz  1 , Karolina R Gonçalves  2 , Lavínia Md Romera  2 , Carolina Borsoi Moraes  3 , Paula Bittencourt-Cunha  2   4 , Sergio Schenkman  4 , Eric Chatelain  1 , Sergio Sosa-Estani  1   5
Affiliations
Review

The translational challenge in Chagas disease drug development

Jadel M Kratz et al. Mem Inst Oswaldo Cruz. .

Abstract

Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi. There is an urgent need for safe, effective, and accessible new treatments since the currently approved drugs have serious limitations. Drug development for Chagas disease has historically been hampered by the complexity of the disease, critical knowledge gaps, and lack of coordinated R&D efforts. This review covers some of the translational challenges associated with the progression of new chemical entities from preclinical to clinical phases of development, and discusses how recent technological advances might allow the research community to answer key questions relevant to the disease and to overcome hurdles in R&D for Chagas disease.

PubMed Disclaimer

Figures

Fig. 1:
Fig. 1:. representation of Trypanosoma cruzi intracellular cycle in mammalian tissues. Trypomastigotes in blood interacts and invade mammalian cells forming a parasitophorous vacuole. The trypomastigotes exit the vacuole and transform into amastigote forms that start multiplying in the host cell cytosol (orange amastigotes). Following multiple rounds of division, amastigotes cease replication via cell cycle arrest (yellow to green amastigotes) and differentiate back into trypomastigotes that can egress and reinvade adjacent cells or circulate in the blood. The diagram also illustrates the existence of early cell cycle arrest in amastigotes (quiescent/dormant forms, light green) that can eventually differentiate back into trypomastigotes. Benznidazole (Bzn) and Posaconazole (Ps) inhibit primarily the intracellular multiplication of amastigotes.
Fig. 2:
Fig. 2:. suggested screening cascade for the identification and progression of new chemical entities for Chagas disease. Assays used in different drug discovery stages (centre), with secondary profiling studies (right) and suggested progression criteria (left). HTS: high-throughput screening; HCS: high-content screening; IC50: half maximal inhibitory concentration; MoA: mechanism of action; PK: pharmacokinetics; ADME: absorption, distribution, metabolism, excretion; BLI: bioluminescent; QD: quaque die (once a day); BID: bis in die (twice a day); PO: oral dosing; PK/PD: pharmacokinetic/pharmacodynamic relationships; Free Cmin: free minimum plasma concentration; H2L: hit-to-lead phase; LO: lead optimisation phase.
Fig. 3:
Fig. 3:. high content screening (HCS) for the discovery of anti-Trypanosoma cruzi compounds. (A) Schematic representation of a general HCS assay setup. Host cell lineage and T. cruzi strains of choice can vary significantly between laboratories and assays. Infected cells are exposed to compounds post-infection for a defined period of time and then antiparasitic activity is evaluated against intracellular amastigotes. Microplates are processed for image analysis. Highly active compounds will result in the (nearly complete) clearance of intracellular amastigotes. (B) Typical images of T. cruzi-infected cells treated with vehicle (left) and an efficacious concentration of benznidazole (right). Raw images are shown in red-stained host cell and parasite, and one key feature of HCS automated image analysis, amastigote segmentation and quantification, is shown in colored lines over grey-colored cells. While efficacious, benznidazole cannot often clear all intracellular amastigotes during short exposure times, and some amastigotes might remain after treatment (arrows).
Fig. 4:
Fig. 4:. bioluminescent in vivo mouse Chagas disease model general scheme for compound efficacy assessment. N: imaging; dX: X days post-infection; t: round of immunosuppression X.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

  • Synthesis and Anti-Trypanosoma cruzi Activity of 3-Cyanopyridine Derivatives.
    Slafer BW, Dessoy MA, de Oliveira RG, Mollo MC, Lee E, Matheeussen A, Maes L, Caljon G, Ferreira LLG, Krogh R, Andricopulo AD, Cruz LR, Mowbray CE, Kratz JM, Dias LC. Slafer BW, et al. ACS Omega. 2024 May 13;9(20):22360-22370. doi: 10.1021/acsomega.4c01919. eCollection 2024 May 21. ACS Omega. 2024. PMID: 38799347 Free PMC article.
  • Short-course combination treatment for experimental chronic Chagas disease.
    González S, Wall RJ, Thomas J, Braillard S, Brunori G, Camino Díaz I, Cantizani J, Carvalho S, Castañeda Casado P, Chatelain E, Cotillo I, Fiandor JM, Francisco AF, Grimsditch D, Keenan M, Kelly JM, Kessler A, Luise C, Lyon JJ, MacLean L, Marco M, Martin JJ, Martinez Martinez MS, Paterson C, Read KD, Santos-Villarejo A, Zuccotto F, Wyllie S, Miles TJ, De Rycker M. González S, et al. Sci Transl Med. 2023 Dec 13;15(726):eadg8105. doi: 10.1126/scitranslmed.adg8105. Epub 2023 Dec 13. Sci Transl Med. 2023. PMID: 38091410 Free PMC article.
  • Strasseriolides display in vitro and in vivo activity against trypanosomal parasites and cause morphological and size defects in Trypanosoma cruzi.
    Bosch-Navarrete C, Pérez-Moreno G, Annang F, Diaz-Gonzalez R, García-Hernández R, Rocha H, Gamarro F, Cordón-Obras C, Navarro M, Rodriguez A, Genilloud O, Reyes F, Vicente F, Ruiz-Pérez LM, González-Pacanowska D. Bosch-Navarrete C, et al. PLoS Negl Trop Dis. 2023 Sep 15;17(9):e0011592. doi: 10.1371/journal.pntd.0011592. eCollection 2023 Sep. PLoS Negl Trop Dis. 2023. PMID: 37713416 Free PMC article.
  • Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors.
    Thomas MG, McGonagle K, Rowland P, Robinson DA, Dodd PG, Camino-Díaz I, Campbell L, Cantizani J, Castañeda P, Conn D, Craggs PD, Edwards D, Ferguson L, Fosberry A, Frame L, Goswami P, Hu X, Korczynska J, MacLean L, Martin J, Mutter N, Osuna-Cabello M, Paterson C, Peña I, Pinto EG, Pont C, Riley J, Shishikura Y, Simeons FRC, Stojanovski L, Thomas J, Wrobel K, Young RJ, Zmuda F, Zuccotto F, Read KD, Gilbert IH, Marco M, Miles TJ, Manzano P, De Rycker M. Thomas MG, et al. J Med Chem. 2023 Aug 10;66(15):10413-10431. doi: 10.1021/acs.jmedchem.3c00582. Epub 2023 Jul 28. J Med Chem. 2023. PMID: 37506194 Free PMC article.
  • State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation.
    Gabaldón-Figueira JC, Martinez-Peinado N, Escabia E, Ros-Lucas A, Chatelain E, Scandale I, Gascon J, Pinazo MJ, Alonso-Padilla J. Gabaldón-Figueira JC, et al. Res Rep Trop Med. 2023 Jun 14;14:1-19. doi: 10.2147/RRTM.S415273. eCollection 2023. Res Rep Trop Med. 2023. PMID: 37337597 Free PMC article. Review.
See all "Cited by" articles

References

    1. WHO WHO fact sheet No 340. 2020. http://www.who.int/mediacentre/factsheets/fs340/en/
    1. Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94. - PubMed
    1. Coura JR. The main sceneries of Chagas disease transmission The vectors, blood and oral transmissions - a comprehensive review. Mem Inst Oswaldo Cruz. 2015;110(3):277–282. - PMC - PubMed
    1. WHO Fourth WHO report on neglected tropical diseases: integrating neglected tropical diseases in global health and development. 2020. https://www.who.int/neglected_diseases/resources/9789241565448/en/
    1. Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi experiences in Argentina. Curr Opin Infect Dis. 2006;19(6):583–587. - PubMed

Substances